Metohexal Retard

Metoprolol succinate, the active ingredient in Metohexal Retard, is a beta blocker presented as an extended‑release tablet for oral use. It treats hypertension, angina pectoris, chronic heart failure and post‑myocardial infarction management in adults.

GNH USA supplies Metohexal Retard as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality and regulatory compliance across markets and providing reliable logistics for global distribution.

Metoprolol succinate is used to manage cardiovascular conditions that involve elevated blood pressure or cardiac workload.

- Hypertension: lowers systolic and diastolic blood pressure to reduce cardiovascular risk. - Angina pectoris: decreases myocardial oxygen demand, relieving chest pain. - Chronic heart failure: improves survival, reduces hospitalizations, and enhances functional capacity. - Post‑myocardial infarction: lowers the risk of recurrent events and mortality after a heart attack.

Metoprolol succinate may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Fatigue: feeling unusually tired or weak. - Dizziness: light‑headedness, especially when standing quickly. - Headache: mild to moderate pain in the head. - Bradycardia: slower than normal heart rate. - Cold extremities: reduced blood flow to hands and feet. - Gastrointestinal upset: nausea, abdominal discomfort.

Serious or Rare Side Effects: - Severe bradycardia or heart block requiring medical attention. - Marked hypotension leading to fainting or shock. - Bronchospasm in patients with asthma or COPD. - Depression or mood changes. - Allergic reactions such as rash, itching, or swelling. - Worsening heart failure symptoms.

Before initiating therapy, consider the following safety measures.

- Monitor blood pressure and heart rate regularly: ensure values remain within therapeutic targets. - Use caution in patients with asthma or chronic obstructive pulmonary disease: β1‑selectivity may not fully prevent bronchoconstriction. - Adjust dose in renal or hepatic impairment: reduced clearance can increase drug exposure. - Avoid abrupt discontinuation: taper gradually to prevent rebound tachycardia or hypertension. - Contraindicated in second‑ or third‑degree atrioventricular block without a pacemaker. - Store below 25°C: keep in the original pack, protect from moisture and direct sunlight.

Metoprolol succinate can interact with several medicines, affecting its safety or efficacy.

Major Interactions (Avoid): - Concomitant use with non‑dihydropyridine calcium channel blockers (verapamil, diltiazem): may cause severe bradycardia or AV block. - Co‑administration with clonidine abrupt withdrawal: can precipitate hypertensive crisis. - MAO inhibitors (phenelzine, tranylcypromine): risk of hypertensive episodes. - Insulin or oral hypoglycemics: may mask hypoglycemia symptoms. - NSAIDs (ibuprofen, naproxen): can diminish antihypertensive effect.

Moderate Interactions (Monitor Closely): - CYP2D6 inhibitors (fluoxetine, paroxetine): increase metoprolol plasma levels. - Diuretics (hydrochlorothiazide, furosemide): may enhance hypotensive response. - Antiplatelet agents (aspirin, clopidogrel): potential for increased bleeding risk.